Promising immunotherapy drug to treat peanut allergies may be approved although 10% of study subjects had serious side effects

x

On [September 13], a panel of experts assembled by the Food and Drug Administration voted that the agency should approve a drug called Palforzia designed to help people manage their peanut allergy. But the non-unanimous verdict rendered by the panel highlights the ongoing debate over whether this therapy, a pill containing peanut protein, is actually worthwhile for patients to take.

The treatment is known as oral immunotherapy, and it works by purposefully exposing someone to a tiny amount of the allergen, with the hope that small doses given over a long enough time can desensitize the person’s hyperactive immune system.

Over 10 percent of people taking Palforzia discontinued the treatment, often because they couldn’t stand the side-effects they experienced. These side-effects included anaphylaxis.

Related article:  ‘Why didn’t we think of this earlier?’ Immunotherapy could treat more than just cancer

Outside researchers have documented these risks, seen across many clinical trials of peanut oral immunotherapy. And given that people are taking the treatment to avoid severe allergic reactions, some have argued that the risks might outweigh the benefits. It was that same rationale that led two of the nine voting experts to recommend against approving the drug.

Read full, original post: The First Peanut Allergy Drug Might Be Approved Soon—but Not Without Controversy

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend